IOBCF OTC

Ion Beam Applications S.A. (IBA) is a company specializing in the design, manufacturing, and ongoing support of sophisticated medical equipment and software solutions primarily focused on treating cancer. Its operations span Belgium, the United States, and various international markets. The company's activities are broadly organized into two main divisions: 1. Proton Therapy and Other Accelerators: This segment is responsible for the engineering, construction, and maintenance of both medical and industrial particle accelerators, including complete proton therapy systems. It also delivers comprehensive, ready-to-use systems for cancer treatment leveraging proton beams. Furthermore, this division produces a variety of cyclotron machines for generating radioisotopes vital for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) imaging, alongside industrial-grade accelerators used in sterilization and ionization processes. 2. Dosimetry: This division offers specialized tools and expert services aimed at enhancing the precision and minimizing errors in radiation oncology treatments, as well as in the quality assurance and calibration protocols for medical imaging systems. IBA actively engages in strategic collaborations, including a key research and development partnership with SCK CEN (the Belgian nuclear research center) focused on enabling the synthesis of Actinium-225 (225Ac), a pioneering radioisotope for cancer therapy. The company also collaborates with the University of Pennsylvania for cutting-edge research into ConformalFLASH technology. Ion Beam Applications S.A. was established in 1986 and maintains its corporate headquarters in Louvain-la-Neuve, Belgium.